crown royalty king queen win
Biotech

J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial

After being touted as a rival to BMS’ reigning psoriasis med Sotyktu for months, J&J’s IL-23 drug looks like it has a shot at taking the crown.
James Waldron Sep 17, 2025 9:45am
heroimageepng

Identifying Undervalued Assets to Address Unmet Patient Needs

Sep 15, 2025 8:00am
weight loss scale weigh measure tape obesity overweight

Lilly rounds out orforglipron data ahead of obesity filings

Sep 17, 2025 9:00am
Businessman climbing steps to pluck a star from the sky

Regeneron's ultrarare disease phase 3 hits, teeing up filings

Sep 17, 2025 9:31am
Two fencers spar in a stadium

Eye disease biotech launches with $100M, Roche rival in clinic

Sep 17, 2025 6:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Roivant reports phase 3 autoimmune win for ex-Pfizer asset

Sep 17, 2025 7:00am
More News

Dexcom CEO goes on leave while Insulet taps new CFO

Sep 17, 2025 12:15pm

FDA warns against unreviewed blood pressure tech, baby monitors

Sep 17, 2025 12:00pm

Fierce Biotech Layoff Tracker 2025: X4, Innate & more

Sep 17, 2025 12:00pm

US VC launches another biotech with China-licensed asset

Sep 17, 2025 10:30am